— Total revenue of $1.6 million during the third quarter of 2018 —
— Recruitment completed for the ReStore soft exo-suit clinical study —
YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced its financial results for the three and nine months ended September 30, 2018.
Highlights of and subsequent to the third quarter include:
- The recruitment requirements have been reached in our multi-center trial of the ReStore exo-suit, and the final participants will be completing the seven session protocol in the coming days.
- On track to file a submission with the Food and Drug Administration (FDA) by year end or early 2019; - Applied for CE mark clearance for the ReStore;
- Placed 500th ReWalk Personal and Rehabilitation system;
- Total revenue for the third quarter of 2018 was $1.6 million compared to $1.7 million in the prior year quarter;
- 22 units were placed during the third quarter of 2018;
- 9 positive coverage decisions in Germany during the third quarter of 2018; and,
- Gross margin improved to 47% during the third quarter of 2018.
“ReWalk has made significant progress to advance our R&D efforts for ReStore and support reimbursement. Positive developments with insurance providers in both the U.S. and Germany suggest we should see increased coverage for the ReWalk exoskeleton for SCI patients as we end 2018 and head into 2019. We have applied for CE mark clearance; and, with our ReStore study enrollment near completion, we are on track to file with the FDA by year end 2018 or early 2019, positioning us to potentially have a stroke product on the market in the U.S. in Q3 2019. We continue to explore all financing options available to the Company in order to ensure that we are able to execute our strategy and advance our important products for the SCI and stroke communities,” stated Larry Jasinski, Chief Executive Officer of ReWalk.
Third Quarter 2018 Financial Results
Total revenue was $1.6 million for the third quarter of 2018, compared to $1.8 million in the second quarter of 2018 and $1.7 million during the prior year quarter. 22 ReWalk systems were placed during the third quarter of 2018, compared to 21 ReWalk systems placed in the prior quarter and 16 systems in the prior year period. 11 systems were placed in the U.S., 9 were placed in our direct markets in Europe and an additional 2 were placed in other markets.
Gross margin improved to 47% during the third quarter of 2018 compared to 41% in the third quarter of 2017, primarily attributable to sales mix and lower product costs.
Total operating expenses in the third quarter of 2018 were $4.9 million compared to $6.1 million in the prior year period.
Net loss was $4.5 million for the third quarter of 2018 compared to a net loss of $5.8 million in the third quarter of 2017. Non-GAAP net loss for the third quarter was $3.8 million compared with a non-GAAP net loss of $4.8 million in the third quarter of 2017. A reconciliation of net loss to non-GAAP net loss is included at the end of this press release.
Liquidity
As of September 30, 2018, ReWalk had $5.2 million in cash on its balance sheet.
Guidance
The Company is updating its full year 2018 revenue guidance and now expects revenues to reach between $7 million and $8 million.
Conference Call
ReWalk management will host its third quarter 2018 conference call as follows:
| Date | Thursday, November 8, 2018 | |
| Time | 4:30 PM EST | |
| Telephone | U.S: | (844) 423-9889 |
| International: | (716) 247-5804 | |
| Israel: | 18 09 31 53 62 | |
| Access code | 6559929 | |
| Webcast (live, listen-only and archive) | www.rewalk.com under the “Investors” section. | |
A telephone replay will be available shortly after the completion of the call for two weeks at (855) 859-2056 (U.S.) or (404) 537-3406 (International). The passcode for the replay is 6559929.
About ReWalk Robotics Ltd.
ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke. ReWalk’s mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany. For more information on the ReWalk systems, please visit www.rewalk.com.
ReWalk® is a registered trademark of ReWalk Robotics Ltd. in Israel and the United States.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding ReWalk’s future performance and, in some cases, may be identified by words like “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “should,” “would,” “seek” and similar terms or phrases. The forward-looking statements contained in this press release are based on management’s current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk’s control. Important factors that could cause ReWalk’s actual results to differ materially from those indicated in the forward-looking statements include, among others: ReWalk’s expectations regarding future growth, including its ability to increase sales in its existing geographic markets, and to expand to new markets and achieve its planned expense reductions; the conclusion of ReWalk’s management and the previous opinion of ReWalk’s auditors in that there are substantial doubts as to ReWalk’s ability to continue as a going concern; ReWalk’s ability to regain compliance with the continued listing requirements of the Nasdaq Capital Market and the risk that its ordinary shares will be delisted if it cannot do so; ReWalk’s ability to maintain and grow its reputation and the market acceptance of its products; ReWalk’s ability to achieve reimbursement from third-party payors for its products; ReWalk’s expectations as to its clinical research program and clinical results; ReWalk’s expectations as to the results of, and the Food and Drug Administration’s potential regulatory developments with respect to, ReWalk’s mandatory post-market 522 surveillance study; the outcome of ongoing shareholder class action litigation relating to ReWalk’s initial public offering; ReWalk’s ability to repay its secured indebtedness; ReWalk’s ability to improve its products and develop new products; the risk that the remaining Timwell Corporation Limited (“Timwell”) issuances will fail to close and the China joint venture will not form, and the resulting effect on ReWalk’s liquidity and financial condition; the risk of substantial dilution resulting from additional issuances, if any, to Timwell; the significant voting power and de facto voting control Timwell may acquire upon additional issuances, if any; ReWalk’s ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; ReWalk’s ability to gain and maintain regulatory approvals; ReWalk’s ability to secure capital from its equity and debt financings in light of limitations under its Form S-3, the price range of its ordinary shares and conditions in the financial markets, and the risk that such financings may dilute ReWalk’s shareholders or restrict its business; ReWalk’s ability to use effectively the proceeds of offerings of securities; the impact of the market price of ReWalk’s ordinary shares on the determination of whether ReWalk is a passive foreign investment company; ReWalk’s ability to maintain relationships with existing customers and develop relationships with new customers; ReWalk’s compliance with medical device reporting regulations to report adverse events involving its products and the potential impact of such adverse events on ReWalk’s ability to market and sell its products; and other factors discussed under the heading “Risk Factors” in ReWalk’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed with the U.S. Securities and Exchange Commission (the “SEC”) and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
Non-GAAP Financial Measures
To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), ReWalk believes that the use of non-GAAP accounting measures, including non-GAAP net loss, is helpful to its investors. These measures, which the Company refers to as non-GAAP financial measures, are not prepared in accordance with GAAP.
For the three- and nine-months ended September 30, 2018 and 2017, non-GAAP net loss is calculated as GAAP net loss excluding (i) non-cash share-based compensation expense, (ii) depreciation and (iii) non-cash financial expenses.
Because of varying available valuation methodologies, subjective assumptions, and the variety of equity instruments that can impact a company’s non-cash expenses, ReWalk believes that providing non-GAAP financial measures that exclude non-cash share-based compensation expense, depreciation and non-cash financial (income) expenses allows for more meaningful comparisons between operating results from period to period. Each of the Company’s non-GAAP financial measures is an important tool for financial and operational decision-making and for the Company’s evaluation of its operating results over different periods of time. The non-GAAP financial data are not measures of the Company’s financial performance under U.S. GAAP, and should not be considered as alternatives to operating loss or net loss or any other performance measures derived in accordance with GAAP. Non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in ReWalk’s industry, as other companies in the industry may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items. In addition, there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, may be different from non-GAAP financial measures used by other companies and exclude expenses that may have a material impact on the Company’s reported financial results. Further, share-based compensation expense has been, and will continue to be for the foreseeable future, a significant recurring expense in the Company’s business and an important part of the compensation provided to its employees. The presentation of non-GAAP financial information is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with GAAP. ReWalk urges investors to review the reconciliation of the Company’s non-GAAP financial measures to the comparable GAAP financial measures included below, and not to rely on any single financial measure to evaluate the Company’s business.
Investor Contact:
Lisa M. Wilson
President
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
(tables follow)
| ReWalk Robotics Ltd. | |||||||||||||||
| Condensed Consolidated Statements of Operations | |||||||||||||||
| In thousands except per share data | |||||||||||||||
| (unaudited) | |||||||||||||||
| Three Months Ended | Nine months ended | ||||||||||||||
| September 30, | September 30, | ||||||||||||||
| 2018 | 2017 | 2018 | 2017 | ||||||||||||
| Revenue | $ | 1,617 | $ | 1,732 | $ | 4,966 | $ | 6,238 | |||||||
| Cost of revenues | 855 | 1,024 | 2,755 | 3,740 | |||||||||||
| Gross profit | 762 | 708 | 2,211 | 2,498 | |||||||||||
| Operating expenses: | |||||||||||||||
| Research and development, net | 1,597 | 1,618 | 5,645 | 4,433 | |||||||||||
| Sales and marketing | 1,926 | 2,637 | 6,187 | 8,643 | |||||||||||
| General and administrative | 1,362 | 1,805 | 5,620 | 5,796 | |||||||||||
| Total operating expenses | 4,885 | 6,060 | 17,452 | 18,872 | |||||||||||
| Operating loss | (4,123 | ) | (5,352 | ) | (15,241 | ) | (16,374 | ) | |||||||
| Loss on extinguishment of debt | - | - | - | 313 | |||||||||||
| Financial expenses, net | 405 | 479 | 1,412 | 1,843 | |||||||||||
| Loss before income taxes | (4,528 | ) | (5,831 | ) | (16,653 | ) | (18,530 | ) | |||||||
| Income taxes | 5 | 15 | 4 | 25 | |||||||||||
| Net loss | $ | (4,533 | ) | $ | (5,846 | ) | $ | (16,657 | ) | $ | (18,555 | ) | |||
| Net loss per ordinary share, basic and diluted | $ | (0.13 | ) | $ | (0.27 | ) | $ | (0.51 | ) | $ | (1.00 | ) | |||
| Weighted average number of shares used in computing net loss per ordinary share, basic and diluted | 35,541,762 | 21,660,757 | 32,809,424 | 18,463,444 | |||||||||||
| Reconciliation of GAAP to Non-GAAP net loss | |||||||||||||||
| Net loss | $ | (4,533 | ) | $ | (5,846 | ) | $ | (16,657 | ) | $ | (18,555 | ) | |||
| Non-cash share based compensation expense | 523 | 899 | 2,342 | 2,597 | |||||||||||
| Depreciation | 122 | 159 | 351 | 516 | |||||||||||
| Non-cash financial expenses | 133 | 21 | 133 | 400 | |||||||||||
| Non-GAAP net loss | $ | (3,755 | ) | $ | (4,767 | ) | $ | (13,831 | ) | $ | (15,042 | ) | |||
| ReWalk Robotics Ltd. | |||||||||||||||
| Condensed Consolidated Balance Sheets | |||||||||||||||
| In thousands | |||||||||||||||
| September 30, | December 31, | ||||||||||||||
| 2018 | 2017 | ||||||||||||||
| Assets | Unaudited | Audited | |||||||||||||
| Current assets | |||||||||||||||
| Cash and cash equivalents | $ | 5,230 | $ | 14,567 | |||||||||||
| Trade receivable, net | 1,163 | 1,103 | |||||||||||||
| Prepaid expenses and other current assets | 1,235 | 1,625 | |||||||||||||
| Inventories | 2,472 | 3,643 | |||||||||||||
| Total current assets | 10,100 | 20,938 | |||||||||||||
| Restricted cash and other long term assets | 1,046 | 1,085 | |||||||||||||
| Property and equipment, net | 728 | 840 | |||||||||||||
| Total assets | $ | 11,874 | $ | 22,863 | |||||||||||
| Liabilities and equity | |||||||||||||||
| Current liabilities | |||||||||||||||
| Current maturities of long term loan | $ | 6,978 | $ | 6,441 | |||||||||||
| Trade payables | 2,778 | 1,811 | |||||||||||||
| Other current liabilities | 1,293 | 1,475 | |||||||||||||
| Total current liabilities | 11,049 | 9,727 | |||||||||||||
| Long term loan | 5,444 | 8,911 | |||||||||||||
| Other long-term liabilities | 602 | 518 | |||||||||||||
| Shareholders’ equity (deficiency) | (5,221 | ) | 3,707 | ||||||||||||
| Total liabilities and equity | $ | 11,874 | $ | 22,863 | |||||||||||
| ReWalk Robotics Ltd. | |||||||||||||||
| Condensed Consolidated Statements of Cash Flows | |||||||||||||||
| In thousands | |||||||||||||||
| (unaudited) | |||||||||||||||
| Nine months ended | |||||||||||||||
| September 30, | |||||||||||||||
| 2018 | 2017 | ||||||||||||||
| Net cash used in operating activities | $ | (12,174 | ) | $ | (17,042 | ) | |||||||||
| Net cash used in investing activities | (3 | ) | (19 | ) | |||||||||||
| Net cash provided by financing activities | 2,823 | 6,341 | |||||||||||||
| Decrease in cash, cash equivalents, and restricted cash | (9,354 | ) | (10,720 | ) | |||||||||||
| Cash, cash equivalents, and restricted cash at beginning of period | 15,423 | 24,498 | |||||||||||||
| Cash, cash equivalents, and restricted cash at end of period | $ | 6,069 | $ | 13,778 | |||||||||||
| ReWalk Robotics Ltd. | |||||||||||||||
| Revenue and Units Placed by Region and Product | |||||||||||||||
| In thousands except units | |||||||||||||||
| (unaudited) | |||||||||||||||
| Three Months Ended | Nine months ended | ||||||||||||||
| September 30, | September 30, | ||||||||||||||
| 2018 | 2017 | 2018 | 2017 | ||||||||||||
| Revenue: | |||||||||||||||
| United States | $ | 962 | $ | 801 | $ | 3,231 | $ | 4,242 | |||||||
| Europe | 553 | 931 | 1,567 | 1,996 | |||||||||||
| Asia Pacific | 2 | - | 10 | - | |||||||||||
| Latin America | - | - | 58 | - | |||||||||||
| Africa | 100 | - | 100 | - | |||||||||||
| Total Revenues | $ | 1,617 | $ | 1,732 | $ | 4,966 | $ | 6,238 | |||||||
| Units Placed: | |||||||||||||||
| United States | 11 | 10 | 38 | 53 | |||||||||||
| Europe | 9 | 6 | 25 | 31 | |||||||||||
| Asia Pacific | - | - | - | - | |||||||||||
| Latin America | - | - | 1 | - | |||||||||||
| Africa | 2 | - | 2 | - | |||||||||||
| Total Units Placed | 22 | 16 | 66 | 84 | |||||||||||
| Revenue: | |||||||||||||||
| Personal units revenue | $ | 1,504 | $ | 1,707 | $ | 4,773 | $ | 6,033 | |||||||
| Rehabilitation units revenue | 113 | 25 | 193 | 205 | |||||||||||
| Total Revenue | $ | 1,617 | $ | 1,732 | $ | 4,966 | $ | 6,238 | |||||||
| Units Placed: | |||||||||||||||
| Personal units placed | 21 | 15 | 64 | 81 | |||||||||||
| Rehabilitation units placed | 1 | 1 | 2 | 3 | |||||||||||
| Total Units Placed | 22 | 16 | 66 | 84 | |||||||||||